Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England
These findings suggest that Gla-300 may offer clinical and economic benefits by reducing hypoglycemia incidents and lowering healthcare costs compared with first-generation BI.
Authors
- N Holden
- Karen Palmer
- Onyinye Diribe
- Amar Puttanna
- Iskandar Idris
- Xiaocong Li Marston (ORCID: https://orcid.org/0000-0002-0025-8197)
- Aymeric Mahieu (ORCID: https://orcid.org/0000-0003-1846-2783)
- Fatemeh Saberi Hosnijeh (ORCID: https://orcid.org/0000-0002-7572-9715)
- Charlie Nicholls
- Nick Denholm
Institutions
- Sanofi (France) (FR)
- Nottingham Biomedical Research Centre (GB)
- Sanofi (United Kingdom) (GB)
Publication Details
- Journal
- BMJ Open Diabetes Research & Care
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/bmjdrc-2025-005027
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi